Abstract
The aim of this study was to investigate efficacy and safety of inhalational treatment with Ruzam in 63 adult patients with persistent mild to moderate atopic bronchial asthma (BA). In this placebo controlled trial, clinical, functional and laboratory parameters were assessed at the end of 2-week treatment with Ruzam and in 6 months after the treatment. All patients also received inhaled corticosteroids. In patients treated with Ruzam, asthma symptoms, bronchial hyperresponsiveness and nitric oxide in the exhaled air decreased and morning PEF increased when compared to patients treated with inhaled corticosteroids plus placebo. During 6 months after the treatment, there were no asthma exacerbations in the Ruzam group and asthma was well-controlled in these patients. The patients treated with Ruzam significantly decreased a frequency of acute respiratory infections. In the control group ( n = 32), exacerbation frequency and asthma control level remained unchanged compared to baseline. Achieving clinical control of asthma in Ruzam group was accompanied by a significant reduction in concentrations of inflammatory markers (IFN-γ, ECP) in serum and in the induced sputum that could be used as a measure of systemic anti-inflammatory effect of Ruzam.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
